Trial Profile

Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary)
Indications Multiple sclerosis
Focus Proof of concept; Therapeutic Use
Acronyms CLAREMI

Most Recent Events

13 Oct 2023 Interim Results ( As of Feb 2023 n=10) assessing Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
20 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com